Track topics on Twitter Track topics that are important to you
Histone Deacetylase 2 Pipeline Review, H2 2019
Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 126.96.36.199 Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and NCOR. It interacts in the late Sphase of DNAreplication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, and CAF1. It deacetylates TSHZ3 and regulates its transcriptional repressor activity.
Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 188.8.131.52 pipeline Target constitutes close to 29 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 1, 12 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Gastrointestinal, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Diffuse Large BCell Lymphoma, Follicular Lymphoma, Melanoma, Mycosis Fungoides, Alzheimer's Disease, BCell NonHodgkin Lymphoma, Breast Cancer, Burkitt Lymphoma, Colorectal Cancer, Cutaneous TCell Lymphoma, Essential Thrombocythemia, Glioblastoma Multiforme GBM, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Lymphoma, Mantle Cell Lymphoma, Marginal Zone Bcell Lymphoma, Multiple Myeloma Kahler Disease, Myelodysplastic Syndrome, Neuroblastoma, NonSmall Cell Lung Cancer, Parkinson's Disease, PostPolycythemia Vera Myelofibrosis PPVMF, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Squamous Cell Carcinoma, TripleNegative Breast Cancer TNBC, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma ACC, Anaplastic Large Cell Lymphoma ALCL, Angioimmunoblastic TCell Lymphoma AITL/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma Basal Cell Epithelioma, Becker Muscular Dystrophy, Bile Duct Cancer Cholangiocarcinoma, Blood Cancer, Bone Disorders, CharcotMarieTooth Disease Type II, Chronic Lymphocytic Leukemia CLL, Chronic Obstructive Pulmonary Disease COPD, CNS Lymphoma, Cognitive Disorders, Colon Cancer, Depression, Duchenne Muscular Dystrophy, Epithelial Ovarian Cancer, Gallbladder Cancer, Gliosarcoma, Hemoglobinopathies, HighGrade Glioma, Human Immunodeficiency Virus HIV Infections AIDS, Human Papillomavirus HPV Associated Cancer, Huntington Disease, Lewy Body Dementia, Liver Fibrosis, Lung Cancer, Merkel Cell Carcinoma, Metastatic Melanoma, Multiple Sclerosis, Myelofibrosis, Natural Killer Cell Lymphomas, Neurodegenerative Diseases, NonHodgkin Lymphoma, NUT Midline Carcinoma NMC or Nuclear Protein in Testis Midline Carcinoma, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral TCell Lymphomas PTCL, Pick Disease, Polycythemia Vera, PostEssential Thrombocythemia Myelofibrosis PostET MF, Prostate Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia CLL, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia CLL, Renal Cell Carcinoma, Sezary Syndrome, Sickle Cell Disease, Solid Tumor, Systemic Lupus Erythematosus and Thalassemia.
The latest report Histone Deacetylase 2 Pipeline Review, H2 2019, outlays comprehensive information on the Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 184.108.40.206 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 220.127.116.11 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 18.104.22.168
The report reviews Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 22.214.171.124 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 126.96.36.199 targeted therapeutics and enlists all their major and minor projects
The report assesses Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 188.8.131.52 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 184.108.40.206 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 220.127.116.11
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 18.104.22.168 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeNEXT ARTICLE
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...